{"id":746087,"date":"2019-02-05T06:45:00","date_gmt":"2019-02-05T06:45:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-for-review-new-drug-application-nda-for-mercks-investigational-combination-of-imipenem-cilastatin-and-relebactam-and-supplemental-nda-snda-for-zerbaxa-ceftolozane-and\/"},"modified":"2025-05-12T08:58:24","modified_gmt":"2025-05-12T12:58:24","slug":"fda-accepts-for-review-new-drug-application-nda-for-mercks-investigational-combination-of-imipenem-cilastatin-and-relebactam-and-supplemental-nda-snda-for-zerbaxa-ceftolozane-and","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-for-review-new-drug-application-nda-for-mercks-investigational-combination-of-imipenem-cilastatin-and-relebactam-and-supplemental-nda-snda-for-zerbaxa-ceftolozane-and\/","title":{"rendered":"FDA Accepts for Review New Drug Application (NDA) for Merck\u2019s Investigational Combination of Imipenem\/Cilastatin and Relebactam, and Supplemental NDA (sNDA) for ZERBAXA\u00ae (Ceftolozane and Tazobactam)"},"content":{"rendered":"<p>KENILWORTH, N.J.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced that the U.S. Food and Drug Administration (FDA) has<br \/>\n      accepted for review regulatory filings for two antibacterial agents.<br \/>\n      These filings are: (1) a NDA accepted for Priority Review for the<br \/>\n      combination of relebactam, the company\u2019s investigational beta-lactamase<br \/>\n      inhibitor, with imipenem\/cilastatin (MK-7655A, IMI\/REL),&nbsp;for the<br \/>\n      treatment of complicated urinary tract infections (cUTI) and complicated<br \/>\n      intra-abdominal infections (cIAI) caused by certain susceptible<br \/>\n      Gram-negative bacteria, in adults with limited or no alternative<br \/>\n      therapies available; and (2) a sNDA accepted for Priority Review for<br \/>\n      ZERBAXA<sup>\u00ae<\/sup> (ceftolozane and tazobactam) to treat adult patients<br \/>\n      with nosocomial pneumonia, including ventilator-associated pneumonia<br \/>\n      caused by certain susceptible Gram-negative microorganisms. The<br \/>\n      Prescription Drug User Fee Act (PDUFA) target action date for IMI\/REL is<br \/>\n      July 16, 2019, while the PDUFA target action date for ZERBAXA is June 3,<br \/>\n      2019.\n    <\/p>\n<p>\n      In the U.S., ZERBAXA is currently indicated for the treatment of adult<br \/>\n      patients with cUTI, including pyelonephritis, caused by certain<br \/>\n      susceptible Gram-negative microorganisms, and is also indicated, in<br \/>\n      combination with metronidazole, for the treatment of adult patients with<br \/>\n      cIAI caused by certain susceptible Gram-negative and Gram-positive<br \/>\n      microorganisms.\n    <\/p>\n<p>\n      Corresponding applications for both medicines have been filed with the<br \/>\n      European Medicines Agency (EMA) and are currently under review.\n    <\/p>\n<p>\n      \u201cThere is a major unmet need for new treatment options to address the<br \/>\n      growing danger of serious and potentially life-threatening infections<br \/>\n      caused by Gram-negative bacteria,\u201d said Dr. Nicholas Kartsonis, senior<br \/>\n      vice president, head of clinical research for infectious diseases and<br \/>\n      vaccines, Merck Research Laboratories. \u201cIn a space where there are<br \/>\n      currently very few treatment options, these filings underscore Merck\u2019s<br \/>\n      ongoing commitment to delivering new antibacterial agents to healthcare<br \/>\n      practitioners and patients.\u201d\n    <\/p>\n<p>\n      The IMI\/REL (MK-7655A) NDA is based on the results of the pivotal Phase<br \/>\n      3 RESTORE-IMI 1 trial, which were presented at the 28th European<br \/>\n      Congress of Clinical Microbiology and Infectious Diseases (ECCMID)<br \/>\n      meeting in Madrid, Spain, in April 2018. The ZERBAXA sNDA is based on<br \/>\n      the pivotal Phase 3 ASPECT-NP trial in adults with ventilated<br \/>\n      hospital-acquired bacterial pneumonia or ventilator-associated bacterial<br \/>\n      pneumonia. Merck plans to present results from the ASPECT-NP study at a<br \/>\n      future scientific conference.\n    <\/p>\n<p>\n      <b>About imipenem, cilastatin and relebactam<\/b>\n    <\/p>\n<p>\n      Relebactam is an investigational, intravenous, class A and C<br \/>\n      beta-lactamase inhibitor currently being evaluated in combination with<br \/>\n      imipenem\/cilastatin for the treatment of certain Gram-negative bacterial<br \/>\n      infections. The FDA has designated the combination of relebactam with<br \/>\n      imipenem\/cilastatin for intravenous use as a Qualified Infectious<br \/>\n      Disease Product (QIDP) with Fast Track status for the treatment of<br \/>\n      complicated urinary tract infections (cUTI), complicated intra-abdominal<br \/>\n      infections (cIAI) and hospital-acquired bacterial<br \/>\n      pneumonia\/ventilator-associated bacterial pneumonia (HABP\/VABP).\n    <\/p>\n<p>\n      <b>About ZERBAXA (ceftolozane and tazobactam)<\/b>\n    <\/p>\n<p>\n      ZERBAXA is an antibacterial combination product for intravenous infusion<br \/>\n      consisting of the cephalosporin antibacterial drug ceftolozane sulfate<br \/>\n      and the beta-lactamase inhibitor tazobactam sodium.\n    <\/p>\n<p>\n      ZERBAXA 1.5g (ceftolozane 1g and tazobactam 0.5g) is approved in the<br \/>\n      United States and is indicated in adult patients for the treatment of<br \/>\n      complicated urinary tract infections (cUTI), including pyelonephritis,<br \/>\n      caused by the following Gram-negative microorganisms:&nbsp;<i>Escherichia<br \/>\n      coli<\/i>,&nbsp;<i>Klebsiella pneumoniae<\/i>,&nbsp;<i>Proteus mirabilis<\/i>,<br \/>\n      and&nbsp;<i>Pseudomonas aeruginosa<\/i>. ZERBAXA used in combination with<br \/>\n      metronidazole is indicated in adult patients for the treatment of<br \/>\n      complicated intra-abdominal infections (cIAI) caused by the following<br \/>\n      Gram-negative and Gram-positive microorganisms:&nbsp;<i>Enterobacter<br \/>\n      cloacae<\/i>,&nbsp;<i>Escherichia coli<\/i>,&nbsp;<i>Klebsiella oxytoca<\/i>,&nbsp;<i>Klebsiella<br \/>\n      pneumoniae<\/i>,&nbsp;<i>Proteus mirabilis<\/i>,&nbsp;<i>Pseudomonas<br \/>\n      aeruginosa<\/i>,&nbsp;<i>Bacteroides fragilis<\/i>, <i>Streptococcus<br \/>\n      anginosus<\/i>,&nbsp;<i>Streptococcus constellatus<\/i>, and&nbsp;<i>Streptococcus<br \/>\n      salivarius<\/i>.\n    <\/p>\n<p>\n      To reduce the development of drug-resistant bacteria and maintain the<br \/>\n      effectiveness of ZERBAXA and other antibacterial drugs, ZERBAXA should<br \/>\n      be used only to treat infections that are proven or strongly suspected<br \/>\n      to be caused by susceptible bacteria. When culture and susceptibility<br \/>\n      information are available, they should be considered in selecting or<br \/>\n      modifying antibacterial therapy. In the absence of such data, local<br \/>\n      epidemiology and susceptibility patterns may contribute to the empiric<br \/>\n      selection of therapy.\n    <\/p>\n<p>\n      <b>Important Safety Information about ZERBAXA (ceftolozane and<br \/>\n      tazobactam)<\/b>\n    <\/p>\n<p>\n      <b>Patients with renal impairment:<\/b>&nbsp;Decreased efficacy of ZERBAXA has<br \/>\n      been observed in patients with baseline creatinine clearance (CrCl) of<br \/>\n      30 to \u226450 mL\/min. In a clinical trial, patients with cIAIs with CrCl &gt;50<br \/>\n      mL\/min had a clinical cure rate of 85.2% when treated with ZERBAXA<br \/>\n      (ceftolozane and tazobactam) plus metronidazole vs. 87.9% when treated<br \/>\n      with meropenem. In the same trial, patients with CrCl 30 to \u226450 mL\/min<br \/>\n      had a clinical cure rate of 47.8% when treated with ZERBAXA plus<br \/>\n      metronidazole vs. 69.2% when treated with meropenem. A similar trend was<br \/>\n      also seen in the cUTI trial. Monitor CrCl at least daily in patients<br \/>\n      with changing renal function and adjust the dose of ZERBAXA accordingly.\n    <\/p>\n<p>\n      <b>Hypersensitivity:<\/b>&nbsp;ZERBAXA is contraindicated in patients with<br \/>\n      known serious hypersensitivity to ceftolozane\/tazobactam,<br \/>\n      piperacillin\/tazobactam, or other members of the beta-lactam class.<br \/>\n      Serious and occasionally fatal hypersensitivity (anaphylactic) reactions<br \/>\n      have been reported in patients receiving beta-lactam antibacterials.<br \/>\n      Before initiating therapy with ZERBAXA, make careful inquiry about<br \/>\n      previous hypersensitivity reactions to cephalosporins, penicillins, or<br \/>\n      other beta-lactams. If an anaphylactic reaction to ZERBAXA occurs,<br \/>\n      discontinue use and institute appropriate therapy.\n    <\/p>\n<p>\n      <i><br \/>\n<b>Clostridium difficile<\/b><br \/>\n<\/i><br \/>\n<b>\u2013associated diarrhea (CDAD),<\/b>&nbsp;ranging<br \/>\n      from mild diarrhea to fatal colitis, has been reported with nearly all<br \/>\n      systemic antibacterial agents, including ZERBAXA. Careful medical<br \/>\n      history is necessary because CDAD has been reported to occur more than<br \/>\n      two months after the administration of antibacterial agents. If CDAD is<br \/>\n      confirmed, antibacterial use not directed against&nbsp;<i>C. difficile&nbsp;<\/i>should<br \/>\n      be discontinued, if possible.\n    <\/p>\n<p>\n      <b>Development of drug-resistant bacteria:<\/b>&nbsp;Prescribing ZERBAXA<br \/>\n      (ceftolozane and tazobactam) in the absence of a proven or strongly<br \/>\n      suspected bacterial infection is unlikely to provide benefit to the<br \/>\n      patient and increases the risk of the development of drug-resistant<br \/>\n      bacteria.\n    <\/p>\n<p>\n      <b>Adverse reactions:<\/b>&nbsp;The most common adverse reactions occurring in<br \/>\n      \u22655% of patients were headache (5.8%) in the cUTI trial, and nausea<br \/>\n      (7.9%), diarrhea (6.2%) and pyrexia (5.6%) in the cIAI trial.\n    <\/p>\n<p>\n      <b>Merck\u2019s commitment to infectious diseases<\/b>\n    <\/p>\n<p>\n      For more than 100 years, Merck has contributed to the discovery and<br \/>\n      development of novel medicines and vaccines to combat infectious<br \/>\n      diseases. In addition to a combined portfolio of vaccines and<br \/>\n      antibacterial, antiviral and antifungal medicines, Merck has multiple<br \/>\n      programs that span discovery through late-stage development. To learn<br \/>\n      more about Merck\u2019s infectious diseases pipeline, visit <a href=\"http:\/\/vip2-msd.com\/merckcom-migrated\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For more than a century, Merck, a leading global biopharmaceutical<br \/>\n      company known as MSD outside of the United States and Canada, has been<br \/>\n      inventing for life, bringing forward medicines and vaccines for many of<br \/>\n      the world\u2019s most challenging diseases. Through our prescription<br \/>\n      medicines, vaccines, biologic therapies and animal health products, we<br \/>\n      work with customers and operate in more than 140 countries to deliver<br \/>\n      innovative health solutions. We also demonstrate our commitment to<br \/>\n      increasing access to health care through far-reaching policies, programs<br \/>\n      and partnerships. Today, Merck continues to be at the forefront of<br \/>\n      research to advance the prevention and treatment of diseases that<br \/>\n      threaten people and communities around the world &#8211; including cancer,<br \/>\n      cardio-metabolic diseases, emerging animal diseases, Alzheimer\u2019s disease<br \/>\n      and infectious diseases including HIV and Ebola. For more information,<br \/>\n      visit <a href=\"http:\/\/vip2-msd.com\/merckcom-migrated\/index.html\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"https:\/\/twitter.com\/Merck\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"https:\/\/www.facebook.com\/MerckInvents\/\" rel=\"nofollow\">Facebook<\/a>,<br \/>\n      <a href=\"https:\/\/www.instagram.com\/merck\/\" rel=\"nofollow\">Instagram<\/a>,<br \/>\n      <a href=\"http:\/\/www.youtube.com\/Merck\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and <a href=\"https:\/\/www.linkedin.com\/company\/merck\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2017 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"https:\/\/www.sec.gov\/\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for ZERBAXA (ceftolozane and<br \/>\n      tazobactam) at&nbsp;<\/b><br \/>\n<a href=\"http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/z\/zerbaxa\/zerbaxa_pi.pdf\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/z\/zerbaxa\/zerbaxa_pi.pdf<\/b><br \/>\n<\/a>\n    <\/p>\n<\/p>\n<p>\n<img decoding=\"async\" alt=\"\" src=\"https:\/\/www.businesswire.com\/images\/spacer.gif\" style=\"width:0;height:0\"><br \/>\n<span class=\"bwct31415\"><br \/>\n<\/span><\/p>\n<p>       Media:<br \/>Pam Eisele<br \/>(267) 305-3558<\/p>\n<p>Sarra Herzog<br \/>(908)        740-1871<\/p>\n<p>Investors:<br \/>Teri Loxam<br \/>(908) 740-1986<\/p>\n<p>Michael        DeCarbo<br \/>(908) 740-1807     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review regulatory filings for two antibacterial agents. These filings are: (1) a NDA accepted for Priority Review for the combination of relebactam, the company\u2019s investigational beta-lactamase inhibitor, with imipenem\/cilastatin (MK-7655A, IMI\/REL),&nbsp;for the treatment of complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI) caused by certain susceptible Gram-negative bacteria, in adults with limited or no alternative therapies available; and (2) a sNDA accepted for Priority Review for ZERBAXA \u00ae (ceftolozane and tazobactam) to treat adult patients with nosocomial pneumonia, including ventilator-associated pneumonia caused by certain susceptible Gram-negative microorganisms. The Prescription Drug User Fee Act (PDUFA) target action date for IMI\/REL is July 16, 2019, while the PDUFA target action<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289,56],"class_list":["post-746087","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>FDA Accepts for Review New Drug Application (NDA) for Merck\u2019s Investigational Combination of Imipenem\/Cilastatin and Relebactam, and Supplemental NDA (sNDA) for ZERBAXA\u00ae (Ceftolozane and Tazobactam) - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-for-review-new-drug-application-nda-for-mercks-investigational-combination-of-imipenem-cilastatin-and-relebactam-and-supplemental-nda-snda-for-zerbaxa-ceftolozane-and\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA Accepts for Review New Drug Application (NDA) for Merck\u2019s Investigational Combination of Imipenem\/Cilastatin and Relebactam, and Supplemental NDA (sNDA) for ZERBAXA\u00ae (Ceftolozane and Tazobactam) - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review regulatory filings for two antibacterial agents. These filings are: (1) a NDA accepted for Priority Review for the combination of relebactam, the company\u2019s investigational beta-lactamase inhibitor, with imipenem\/cilastatin (MK-7655A, IMI\/REL),&nbsp;for the treatment of complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI) caused by certain susceptible Gram-negative bacteria, in adults with limited or no alternative therapies available; and (2) a sNDA accepted for Priority Review for ZERBAXA \u00ae (ceftolozane and tazobactam) to treat adult patients with nosocomial pneumonia, including ventilator-associated pneumonia caused by certain susceptible Gram-negative microorganisms. The Prescription Drug User Fee Act (PDUFA) target action date for IMI\/REL is July 16, 2019, while the PDUFA target action\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-for-review-new-drug-application-nda-for-mercks-investigational-combination-of-imipenem-cilastatin-and-relebactam-and-supplemental-nda-snda-for-zerbaxa-ceftolozane-and\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-12T12:58:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.businesswire.com\/images\/spacer.gif\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-accepts-for-review-new-drug-application-nda-for-mercks-investigational-combination-of-imipenem-cilastatin-and-relebactam-and-supplemental-nda-snda-for-zerbaxa-ceftolozane-and\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-accepts-for-review-new-drug-application-nda-for-mercks-investigational-combination-of-imipenem-cilastatin-and-relebactam-and-supplemental-nda-snda-for-zerbaxa-ceftolozane-and\\\/\",\"name\":\"FDA Accepts for Review New Drug Application (NDA) for Merck\u2019s Investigational Combination of Imipenem\\\/Cilastatin and Relebactam, and Supplemental NDA (sNDA) for ZERBAXA\u00ae (Ceftolozane and Tazobactam) - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-accepts-for-review-new-drug-application-nda-for-mercks-investigational-combination-of-imipenem-cilastatin-and-relebactam-and-supplemental-nda-snda-for-zerbaxa-ceftolozane-and\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-accepts-for-review-new-drug-application-nda-for-mercks-investigational-combination-of-imipenem-cilastatin-and-relebactam-and-supplemental-nda-snda-for-zerbaxa-ceftolozane-and\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.businesswire.com\\\/images\\\/spacer.gif\",\"datePublished\":\"2019-02-05T06:45:00+00:00\",\"dateModified\":\"2025-05-12T12:58:24+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-accepts-for-review-new-drug-application-nda-for-mercks-investigational-combination-of-imipenem-cilastatin-and-relebactam-and-supplemental-nda-snda-for-zerbaxa-ceftolozane-and\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-accepts-for-review-new-drug-application-nda-for-mercks-investigational-combination-of-imipenem-cilastatin-and-relebactam-and-supplemental-nda-snda-for-zerbaxa-ceftolozane-and\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-accepts-for-review-new-drug-application-nda-for-mercks-investigational-combination-of-imipenem-cilastatin-and-relebactam-and-supplemental-nda-snda-for-zerbaxa-ceftolozane-and\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.businesswire.com\\\/images\\\/spacer.gif\",\"contentUrl\":\"https:\\\/\\\/www.businesswire.com\\\/images\\\/spacer.gif\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-accepts-for-review-new-drug-application-nda-for-mercks-investigational-combination-of-imipenem-cilastatin-and-relebactam-and-supplemental-nda-snda-for-zerbaxa-ceftolozane-and\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FDA Accepts for Review New Drug Application (NDA) for Merck\u2019s Investigational Combination of Imipenem\\\/Cilastatin and Relebactam, and Supplemental NDA (sNDA) for ZERBAXA\u00ae (Ceftolozane and Tazobactam)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FDA Accepts for Review New Drug Application (NDA) for Merck\u2019s Investigational Combination of Imipenem\/Cilastatin and Relebactam, and Supplemental NDA (sNDA) for ZERBAXA\u00ae (Ceftolozane and Tazobactam) - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-for-review-new-drug-application-nda-for-mercks-investigational-combination-of-imipenem-cilastatin-and-relebactam-and-supplemental-nda-snda-for-zerbaxa-ceftolozane-and\/","og_locale":"en_US","og_type":"article","og_title":"FDA Accepts for Review New Drug Application (NDA) for Merck\u2019s Investigational Combination of Imipenem\/Cilastatin and Relebactam, and Supplemental NDA (sNDA) for ZERBAXA\u00ae (Ceftolozane and Tazobactam) - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review regulatory filings for two antibacterial agents. These filings are: (1) a NDA accepted for Priority Review for the combination of relebactam, the company\u2019s investigational beta-lactamase inhibitor, with imipenem\/cilastatin (MK-7655A, IMI\/REL),&nbsp;for the treatment of complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI) caused by certain susceptible Gram-negative bacteria, in adults with limited or no alternative therapies available; and (2) a sNDA accepted for Priority Review for ZERBAXA \u00ae (ceftolozane and tazobactam) to treat adult patients with nosocomial pneumonia, including ventilator-associated pneumonia caused by certain susceptible Gram-negative microorganisms. The Prescription Drug User Fee Act (PDUFA) target action date for IMI\/REL is July 16, 2019, while the PDUFA target action","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-for-review-new-drug-application-nda-for-mercks-investigational-combination-of-imipenem-cilastatin-and-relebactam-and-supplemental-nda-snda-for-zerbaxa-ceftolozane-and\/","og_site_name":"Merck.com","article_modified_time":"2025-05-12T12:58:24+00:00","og_image":[{"url":"https:\/\/www.businesswire.com\/images\/spacer.gif","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-for-review-new-drug-application-nda-for-mercks-investigational-combination-of-imipenem-cilastatin-and-relebactam-and-supplemental-nda-snda-for-zerbaxa-ceftolozane-and\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-for-review-new-drug-application-nda-for-mercks-investigational-combination-of-imipenem-cilastatin-and-relebactam-and-supplemental-nda-snda-for-zerbaxa-ceftolozane-and\/","name":"FDA Accepts for Review New Drug Application (NDA) for Merck\u2019s Investigational Combination of Imipenem\/Cilastatin and Relebactam, and Supplemental NDA (sNDA) for ZERBAXA\u00ae (Ceftolozane and Tazobactam) - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-for-review-new-drug-application-nda-for-mercks-investigational-combination-of-imipenem-cilastatin-and-relebactam-and-supplemental-nda-snda-for-zerbaxa-ceftolozane-and\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-for-review-new-drug-application-nda-for-mercks-investigational-combination-of-imipenem-cilastatin-and-relebactam-and-supplemental-nda-snda-for-zerbaxa-ceftolozane-and\/#primaryimage"},"thumbnailUrl":"https:\/\/www.businesswire.com\/images\/spacer.gif","datePublished":"2019-02-05T06:45:00+00:00","dateModified":"2025-05-12T12:58:24+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-for-review-new-drug-application-nda-for-mercks-investigational-combination-of-imipenem-cilastatin-and-relebactam-and-supplemental-nda-snda-for-zerbaxa-ceftolozane-and\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-for-review-new-drug-application-nda-for-mercks-investigational-combination-of-imipenem-cilastatin-and-relebactam-and-supplemental-nda-snda-for-zerbaxa-ceftolozane-and\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-for-review-new-drug-application-nda-for-mercks-investigational-combination-of-imipenem-cilastatin-and-relebactam-and-supplemental-nda-snda-for-zerbaxa-ceftolozane-and\/#primaryimage","url":"https:\/\/www.businesswire.com\/images\/spacer.gif","contentUrl":"https:\/\/www.businesswire.com\/images\/spacer.gif"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-for-review-new-drug-application-nda-for-mercks-investigational-combination-of-imipenem-cilastatin-and-relebactam-and-supplemental-nda-snda-for-zerbaxa-ceftolozane-and\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"FDA Accepts for Review New Drug Application (NDA) for Merck\u2019s Investigational Combination of Imipenem\/Cilastatin and Relebactam, and Supplemental NDA (sNDA) for ZERBAXA\u00ae (Ceftolozane and Tazobactam)"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"82cc32d2-1700-41d8-a114-702cf58b480f","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/FDA-Accepts-for-Review-New-Drug-Application-NDA-for-Mercks-Investigational-Combination-of-ImipenemCilastatin-and-Relebactam-and-Suppl-T3MCV.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/746087","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/746087\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=746087"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=746087"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}